Sensyne Health: Well placed to accelerate its commercial plans

0
18
  • Sensyne Health launches AI-based life sciences analytics platform
  • Sensyne Health’s new SENSIGHT platform can help double value says broker
  • Shield Therapeutics’ get to work ahead of US launch of Accrufer in June
xxxxxxx

Quick facts: Sensyne Health PLC

Follow

View company profile

Sensyne Health PLC is a clinical artificial intelligence company operating a unique business model – a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.

The company applies clinical AI in the healthcare and life science industries.

In healthcare, Sensyne delivers remote patient monitoring and real time decision making systems for healthcare organizations and their patients.

In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

09 Sep 2021

(, ) launched an AI-enabled global data analytics platform for the healthcare and life sciences sectors.

Called SENSIGHT, the platform uses data derived from around 10mln anonymised and de-identified patients accumulated from research partnerships with NHS Trusts and US health systems.

It is the first platform of its type to provide industrial-scale access for research, said the AIM-listed group, with the plan to add new tools and grow the database to 100mln patients by the end of 2024.

Available by subscription at a cost of GBP25,000 per person per year for commercial customers, the system will be free to NHS Trust partners.

Read more

02 Sep 2021

(, ) said it signed a research agreement with Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH).

The five-year non-exclusive partnership is to analyse anonymised patient data using clinical artificial intelligence technology.

Read more

19 Aug 2021

(, ) (LON: SENS) has signed a strategic research agreement with a US healthcare group giving it access to “de-identified” data from its 3.6mln patients.

The latest tie-up is with Sentara Healthcare, which covers Virginia and north-eastern North Carolina through 12 acute hospitals with more than 300 other sites.

Read more

09 Sep 2021

Sensyne PLC’s new patient data analytics platform SENSIGHT can help double the AIM-listed’s group value according to the house broker Liberum.

SENSIGHT will cost subscribers GBP25,000 per user per annum and initially gives access to a database of 2m patient records.

The depth of the product will rapidly grow, however, believes Liberum, reaching 10mln by year-end, and accelerating thereafter.

Read more

21 May 2021

() Tim Watts updates investors on its track to launch Accrufer, its iron deficiency treatment, in the US by the end of next month.

Preparatory work on the launch has accelerated dramatically, the firms has established a US subsidiary and set up the necessary operating essentials for the launch.

Work is in progress on the product supply chain and logistics and all being well, launch stocks should be in its US wholesaler’s warehouses by mid-June.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

JD Sports gets angry while Melrose shareholders are more than happy

The FTSE 100 edged higher as investors looked forward to tomorrow’s US jobs data. BHP’s huge payout going ex- dividend was a drag but London’s blue-chip index was up six at 7,156 in early trades.

Barratt Developments profits rebounded by 65% in its latest financial year as it added the…

1 week ago

5 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here